The development of a new enzyme for double strand oligonucleotide formation with high productivity has been announced by Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services. Aji Bio-Pharma collaborated with researchers from the University of Shizuoka to develop a highly functional artificial RNA ligase using the ancestral design method. The new artificial RNA ligase was found to have higher thermostability than natural RNA ligase and superior ligation activity for RNA fragments containing xenonucleic acid. This new approach enables more productive and environmentally safe oligonucleotide synthesis when compared to the conventional method, and is expected to be applied in the mass production of nucleic acid drugs with high efficiency and high purity.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!